Cost-Effectiveness of Pazopanib: An Example of Improved Transparency and Accessibility of Industry-Sponsored Economic Evaluations through Publication in Peer-Reviewed Journals
Excerpt
We congratulate Amdahl et al. on publishing their paper about the cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma (mrcc) in Canada. [...]
Share and Cite
Beca, J.; Chan, K.K.W. Cost-Effectiveness of Pazopanib: An Example of Improved Transparency and Accessibility of Industry-Sponsored Economic Evaluations through Publication in Peer-Reviewed Journals. Curr. Oncol. 2016, 23, 327-329. https://doi.org/10.3747/co.22.2741
Beca J, Chan KKW. Cost-Effectiveness of Pazopanib: An Example of Improved Transparency and Accessibility of Industry-Sponsored Economic Evaluations through Publication in Peer-Reviewed Journals. Current Oncology. 2016; 23(4):327-329. https://doi.org/10.3747/co.22.2741
Chicago/Turabian StyleBeca, J., and K.K.W. Chan. 2016. "Cost-Effectiveness of Pazopanib: An Example of Improved Transparency and Accessibility of Industry-Sponsored Economic Evaluations through Publication in Peer-Reviewed Journals" Current Oncology 23, no. 4: 327-329. https://doi.org/10.3747/co.22.2741